A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Melanoma vaccine gp100; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
- 26 Jun 2013 Biomarkers information updated
- 12 Oct 2005 New trial record.